Association of liver abnormalities with in-hospital mortality in patients with COVID-19
Ze-yang Ding,Gan-xun Li,Lin Chen,Chang Shu,Jia Song,Wei Wang,Yu-wei Wang,Qian Chen,Guan-nan Jin,Tong-tong Liu,Jun-nan Liang,Peng Zhu,Wei Zhu,Yong Li,Bin-hao Zhang,Huan Feng,Wan-guang Zhang,Zhen-yu Yin,Wen-kui Yu,Yang Yang,Hua-qiu Zhang,Zhou-ping Tang,Hui Wang,Jun-bo Hu,Ji-hong Liu,Ping Yin,Xiao-ping Chen,Bixiang Zhang,Tongji Multidisciplinary Team for Treating COVID-19
DOI: https://doi.org/10.1016/j.jhep.2020.12.012
IF: 25.7
2021-06-01
Journal of Hepatology
Abstract:BACKGROUND & AIMS: <AbstractText Label="BACKGROUND &amp; AIMS">The evolution and clinical significance of abnormal liver chemistries and the impact of hepatitis B infection on outcome in patients with COVID-19 is not well characterized. This study aimed to explore these issues.</AbstractText>METHODS: <AbstractText Label="METHODS">This large retrospective cohort study included 2,073 patients with coronavirus disease 2019 (COVID-19) and definite outcomes in Wuhan, China. Longitudinal liver function tests were conducted, with associated factors and risk of death determined by multivariate regression analyses. A prognostic nomogram was formulated to predict the survival of patients with COVID-19. The characteristics of liver abnormalities and outcomes of patients with COVID-19, with and without hepatitis B, were compared after 1:3 propensity score matching.</AbstractText>RESULTS: <AbstractText Label="RESULTS">Of the 2,073 patients, 1,282 (61.8%) had abnormal liver chemistries during hospitalization, and 297 (14.3%) had a liver injury. The mean levels of aspartate aminotransferase (AST) and direct bilirubin (D-Bil) increased early after symptom onset in deceased patients and showed disparity compared to levels in discharged patients throughout the clinical course of the disease. Abnormal AST (adjusted hazard ratio [HR] 1.39; 95% CI 1.04-1.86, p = 0.027) and D-Bil (adjusted HR 1.66; 95% CI 1.22-2.26; p = 0.001) levels at admission were independent risk factors for mortality due to COVID-19. A nomogram was established based on the results of multivariate analysis and showed sufficient discriminatory power and good consistency between the prediction and the observation. HBV infection in patients did not increase the risk of poor COVID-19-associated outcomes.</AbstractText>CONCLUSIONS: <AbstractText Label="CONCLUSIONS">Abnormal AST and D-Bil levels at admission were independent predictors of COVID-19-related mortality. Therefore, monitoring liver chemistries, especially AST and D-Bil levels, is necessary in hospitalized patients with COVID-19.</AbstractText>LAY SUMMARY: <AbstractText Label="LAY SUMMARY">Liver test abnormalities (in particular elevations in the levels of aspartate aminotransferase [AST] and direct bilirubin [D-Bil]) were observed after symptom onset in patients who went on to die of coronavirus disease 2019 (COVID-19). Abnormal levels of AST and D-Bil at admission were independent predictors of COVID-19-related mortality. HBV infection in patients did not increase the risk of poor COVID-19-associated outcomes.</AbstractText>
gastroenterology & hepatology